The Zacks Analyst Blog Highlights:JPMorgan Chase, Bank of America, Citigroup, Wells Fargo and Covidien

Jan 22, 2013, 09:30 ET from Zacks Investment Research, Inc.

CHICAGO, Jan. 22, 2013 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include JPMorgan Chase & Co. (NYSE: JPM), Bank of America Corporation (NYSE: BAC), Citigroup Inc. (NYSE: C), Wells Fargo & Company (NYSE: WFC) and Covidienplc. (NYSE: COV).


Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Monday's Analyst Blog:

Foreclosure Activity Slowing Down

Signaling a steady recovery in the housing market, the foreclosure market report released by RealtyTrac revealed a slump in the overall foreclosure activity in 2012. As per this leading online marketplace of foreclosure properties, foreclosure filings slipped 3% from 2011 and plunged 36% from 2010. This brought the aggregate number of properties receiving default, auction or repossession notices to 1,836,634.

Though overall foreclosure activity dipped in 2012, it hiked in 25 states on a year-over-year basis. Out of these, 20 states use the judicial foreclosure process. Yet, foreclosure activity fell in 25 states (19 of these states use the non-judicial foreclosure process) from the 2011 levels. The top 10 states with the highest foreclosure rates were Florida, Nevada, Arizona, Georgia, Illinois, California, Ohio, Michigan, South Carolina and Colorado.

Further, by the end of 2012, above 1.5 million homes were at some stage of foreclosure process or bank-owned, rising 9% from the end of 2011, but down 31% from the end of 2010. Nevertheless, the rise in property prices enabled many homeowners to come out of negative equity. In Jan 2013, nearly 10.9 million homeowners across the country were underwater, down from 12.5 million in Jan 2012.

Decline in overall foreclosure activity was largely due to the switching of mortgage servicers and the government to other options – short sale, refinancing of loans and loan modifications – to prevent foreclosures. However, the dip in foreclosures is expected to be at an uneven pace, as processes that are being used in handling these vary from state to state.

Foreclosure activity is expected to rise in judicial states early this year as these states have substantial backlogs to clear. Further, there would be another wave of rise at the end of year in non-judicial states as major lenders – JPMorgan Chase & Co. (NYSE: JPM), Bank of America Corporation (NYSE: BAC), Citigroup Inc. (NYSE: C), Ally Financial Inc. and Wells Fargo & Company (NYSE: WFC) – adjust to the new rules set under the National Mortgage Settlement as well as several other laws.

Yet, we believe that the gradually stabilizing housing sector and falling unemployment rate are likely to aid homeowners to avoid foreclosures in the near term. Also, the rate at which properties are entering the foreclosure procedure is expected to trend down gradually, thereby lifting the housing prices going forward. Moreover, the housing market will get an opportunity to regain a solid foothold if there are sufficient buyers for these properties.

Covidien Reveals OneShot for Hypertension

International health care product major, Covidienplc. (NYSE: COV) recently revealed the commercialization of its OneShot Renal Denervation System. This offering is used to treat hypertension. OneShot received CE Mark approval in early 2012. It will be launched in EMEA and Latin America in the next few months. 

Hypertension afflicts about a billion people globally. It is a chronic state that places victims at greater risk of heart disease, kidney problems and stroke. 10% to 15% of hypertension patients do not respond to standard therapy. Such patients are expected to benefit from OneShot, which is an offering with less procedure time than other options. 

Covidien is a leading global health care product manufacturing company that develops and markets medical solutions for better patient outcomes. It has a history of developing and manufacturing high-quality products in a cost-effective manner. Covidien continues to expand both organically as well as inorganically, despite a challenging Med-tech environment.

We see opportunities for multiple expansion, based on the strength and diversity of the company's business and its ability to grow on the back of strategic investments and portfolio reshaping initiatives toward high-growth/high-margin businesses. Additionally, the exit of a competitor has created opportunities for the company to gain market share in the U.S.

Further, Covidien remains committed to delivering incremental returns to its investors. The company raised its commitment to return more than 50% of its free cash flow to shareholders via dividends and share repurchases.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.